NASDAQ:CHTP - Chelsea Therapeutics International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Chelsea Therapeutics International logoChelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson's Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.

Receive CHTP News and Ratings via Email

Sign-up to receive the latest news and ratings for CHTP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CHTP
CUSIPN/A
Phone+1-704-3411516

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

The Truth About Cryptocurrencies

Chelsea Therapeutics International (NASDAQ:CHTP) Frequently Asked Questions

What is Chelsea Therapeutics International's stock symbol?

Chelsea Therapeutics International trades on the NASDAQ under the ticker symbol "CHTP."

Has Chelsea Therapeutics International been receiving favorable news coverage?

News headlines about CHTP stock have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chelsea Therapeutics International earned a news sentiment score of 0.10 on Accern's scale. They also gave media coverage about the healthcare company an impact score of 47.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Chelsea Therapeutics International?

Shares of CHTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Chelsea Therapeutics International?

Chelsea Therapeutics International's mailing address is 3530 Toringdon Way Ste 200, CHARLOTTE, NC 28277-3436, United States. The healthcare company can be reached via phone at +1-704-3411516.


MarketBeat Community Rating for Chelsea Therapeutics International (CHTP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Chelsea Therapeutics International and other stocks. Vote "Outperform" if you believe CHTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHTP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.